Condition: Non-hodgkin Lymphoma · Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Sponsor: Hangzhou Zenshine Pharmaceuticals Co., Ltd.
ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A administered orally (PO) once daily (QD) in 28-day cycles in patients with relapsed/resistant or refractory advanced hematologic malignancies \[Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Gilbert, Arizona, United States | — |
| ACRC/Arizona Clinical Research Center, Inc. | Tucson, Arizona, United States | — |
| Innovative Clinical Research Institute | Long Beach, California, United States | — |
| New Jersey Center for Cancer Research | Brick, New Jersey, United States | — |
| University of Toledo Precision Oncology Research | Toledo, Ohio, United States | — |
| Seattle Cancer Care Alliance | Seattle, Washington, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04504708